Awaiting development: Guidance and quality standards

Showing 1 to 10 of 322

Guidance and quality standards awaiting development
Title	Type
12 SQ-HDM SLIT for treating allergic rhinitis or rhinoconjunctivitis caused by house dust mites in children 5 to 11 years [ID6510]	Technology appraisal guidance
Abatacept for treating active idiopathic inflammatory myopathies [TSID10095]	Technology appraisal guidance
Abilify MyCite for treating bipolar disorder 1 or schizophrenia [ID3833]	Technology appraisal guidance
Acalabrutinib for treating relapsed or refractory mantle cell lymphoma [ID6389]	Technology appraisal guidance
Acalabrutinib with venetoclax and obinutuzumab for untreated chronic lymphocytic leukaemia [ID6156]	Technology appraisal guidance
Adalimumab for treating early Dupuytren's contracture [ID6276]	Technology appraisal guidance
Afamitresgene autoleucel for previously treated MAGE-A4 positive advanced synovial sarcoma or myxoid round cell liposarcoma [ID4064]	Technology appraisal guidance
Aficamten for treating symptomatic obstructive hypertrophic cardiomyopathy [TSID12185]	Technology appraisal guidance
AI and novel technologies in lung function measurement	Health technology evaluation
Alpelisib for treating severe PIK3CA-related overgrowth spectrum in people 2 years and over [ID6252]	Technology appraisal guidance